Immune Design Corp. (NASDAQ:IMDZ) major shareholder Leo Guthart bought 10,000 shares of the stock in a transaction on Monday, September 18th. The shares were bought at an average price of $9.70 per share, for a total transaction of $97,000.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of Immune Design Corp. (IMDZ) opened at 10.50 on Friday. Immune Design Corp. has a 12-month low of $4.50 and a 12-month high of $13.05. The firm’s market cap is $269.00 million. The stock’s 50 day moving average price is $9.58 and its 200 day moving average price is $8.01.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. On average, equities research analysts predict that Immune Design Corp. will post ($2.34) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Leo Guthart Purchases 10,000 Shares of Immune Design Corp. (IMDZ) Stock” was posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.dailypolitical.com/2017/09/24/leo-guthart-purchases-10000-shares-of-immune-design-corp-imdz-stock.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. grew its position in Immune Design Corp. by 2.1% during the 2nd quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock worth $19,281,000 after purchasing an additional 40,010 shares in the last quarter. Franklin Resources Inc. grew its position in Immune Design Corp. by 2.7% during the 2nd quarter. Franklin Resources Inc. now owns 760,253 shares of the biotechnology company’s stock worth $7,412,000 after purchasing an additional 20,000 shares in the last quarter. JPMorgan Chase & Co. grew its position in Immune Design Corp. by 118.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock worth $5,175,000 after purchasing an additional 288,009 shares in the last quarter. Vanguard Group Inc. grew its position in Immune Design Corp. by 37.9% during the 2nd quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock worth $5,118,000 after purchasing an additional 144,408 shares in the last quarter. Finally, FMR LLC grew its position in Immune Design Corp. by 0.4% during the 1st quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock worth $3,027,000 after purchasing an additional 1,699 shares in the last quarter. Hedge funds and other institutional investors own 51.46% of the company’s stock.

A number of brokerages have commented on IMDZ. ValuEngine upgraded Immune Design Corp. from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Royal Bank Of Canada began coverage on Immune Design Corp. in a report on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price on the stock. Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a report on Tuesday, June 6th. BidaskClub cut Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $18.00 target price on shares of Immune Design Corp. in a report on Wednesday, June 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $16.33.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.